P
Peter Smith-Jones
Researcher at Stony Brook University
Publications - 86
Citations - 8648
Peter Smith-Jones is an academic researcher from Stony Brook University. The author has contributed to research in topics: Radioimmunotherapy & Prostate cancer. The author has an hindex of 39, co-authored 86 publications receiving 7613 citations. Previous affiliations of Peter Smith-Jones include University of Vienna & Cornell University.
Papers
More filters
Journal ArticleDOI
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran,Samedy Ouk,Nicola J. Clegg,Yu Chen,Philip A. Watson,Vivek K. Arora,John Wongvipat,Peter Smith-Jones,Dongwon Yoo,Andrew Kwon,Teresa Wasielewska,Derek S. Welsbie,Charlie D. Chen,Celestia S. Higano,Tomasz M. Beer,David T. Hung,Howard I. Scher,Michael E. Jung,Charles L. Sawyers +18 more
TL;DR: The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.
Journal ArticleDOI
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg,John Wongvipat,James Joseph,Chris Tran,Samedy Ouk,Anna Dilhas,Yu Chen,Kate Grillot,Eric D. Bischoff,Ling Cai,Anna Aparicio,Steven Dorow,Vivek K. Arora,Gang Shao,Jing Qian,Hong Zhao,Guangbin Yang,Chunyan Cao,John Sensintaffar,Teresa Wasielewska,Herbert Mark R,Celine Bonnefous,Beatrice Darimont,Howard I. Scher,Peter Smith-Jones,Mark Klang,Nicholas D. Smith,Elisa de Stanchina,Nian Wu,Ouathek Ouerfelli,Peter J. Rix,Richard A. Heyman,Michael E. Jung,Charles L. Sawyers,Jeffrey H. Hager +34 more
TL;DR: ARS-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists, and offers preclinical proof of principle for ARN-509 as a promising therapeutic in bothCastration-sensitive and castration-resistant forms of prostate cancer.
Journal ArticleDOI
Biodistribution and delivery efficiency of unmodified tumor-derived exosomes.
Tyson Smyth,Max Kullberg,Noeen Malik,Peter Smith-Jones,Michael W. Graner,Thomas J. Anchordoquy +5 more
TL;DR: Comparisons to liposomal formulations revealed the significance of the innate immune system along with the complement protein C5 on exosomes' rate of clearance and biodistribution, and limits their use as an anti-cancer drug delivery vehicle.
Journal ArticleDOI
89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
Jason P. Holland,Vadim Divilov,Neil H. Bander,Peter Smith-Jones,Steven M. Larson,Jason S. Lewis +5 more
TL;DR: It is demonstrated that 89Zr-DFO–labeled mAbs show exceptional promise as radiotracers for immunoPET of human cancers and can be used to delineate and quantify PSMA-positive prostate tumors in vivo.
Journal ArticleDOI
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
TL;DR: A method for imaging the inhibition of Hsp90 by 17-AAG by labeling an F(ab′)2 fragment of the anti-HER2 antibody Herceptin with 68Ga, a positron emitter, which allows the sequential positron-emission tomographic imaging of HER2 expression.